A review of first line infertility treatments and supporting evidence in women with polycystic ovary syndrome.
journal contributionposted on 2021-12-10, 10:57 authored by Michael Costello, Rhonda Garad, Roger Hart, Hayden Homer, Louise Johnson, Cailin Jordan, Edgar MocanuEdgar Mocanu, Jie Qiao, Luk Rombauts, Helena J Teede, Eszter Vanky, Christos Venetis, William Ledger
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility in women of reproductive age. Lifestyle change is considered the first line treatment for the management of infertile anovulatory women with PCOS, and weight loss for those who are overweight or obese. First line medical ovulation induction therapy to improve fertility outcomes is letrozole, whilst other less efficacious ovulation induction agents, such as clomiphene citrate, metformin, and metformin combined with clomiphene citrate, may also be considered. Metformin combined with clomiphene citrate is more effective than clomiphene citrate alone. In obese women with PCOS, clomiphene citrate could be used in preference to metformin alone whilst clomiphene citrate could be added to metformin alone in order to improve reproductive outcome in all women with PCOS. Gonadotrophins, which are more effective than clomiphene citrate in therapy naïve women with PCOS, can be considered a first line therapy in the presence of ultrasound monitoring, following counselling on the cost and the potential risk of multiple pregnancy.
CommentsThe original article is available at https://www.mdpi.com
Published CitationCostello M. et al. A review of first line infertility treatments and supporting evidence in women with polycystic ovary syndrome. Med Sci (Basel). 2019;7(9):95.
Publication Date10 September 2019
- Obstetrics and Gynaecology
- Published Version (Version of Record)